Fig. 2: Cellular immune response to EBOV GP peptides as measured by IFNγ ELISpot. | Nature Communications

Fig. 2: Cellular immune response to EBOV GP peptides as measured by IFNγ ELISpot.

From: Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic

Fig. 2

a Response to 187 individual glycoprotein peptides amongst 15 fresh PBMC samples. Bars are stacked and indicate the sum of all results to each peptide amongst 15 EVD survivors. b Response amongst 6 EVD survivors to individual 15 mer peptides which make up the SP peptide pool. c The response amongst 12 EVD survivors to individual 15 mer peptides that make up the GP1-1 peptide pool. d Response amongst 18 EVD survivors to individual 15 mer peptides which make up the GP1-2 peptide pool. e The response amongst 14 EVD survivors to individual 15 mer peptides that make up the GP1-4 peptide pool. For graphs (b–e) red dots indicate individual data points and bars with error represent the median with the upper 95% confidence interval. Black dashed line represents the lower limit of detection (LLD) for the GP1-2 (19 SFU) or GP1-4 (16 SFU) peptide pool respectively, this was calculated using the mean of the negative samples plus three SD.

Back to article page